Increased plasma soluble CD40 ligand concentration in pelvic inflammatory disease

Tsung chin Ho, Shun Fa Yang, Po Hui Wang, Long Yau Lin, Yi Torng Tee, Wen Chun Liao, Hsiu-Ju Chang, Hsiu-Ting Tsai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The role of soluble CD40 ligand (sCD40L) in pelvic inflammatory disease (PID) remains unclear. We sought to determine whether sCD40L was an efficient serum marker as with WBC and CRP in PID patients. Methods: Enzyme-linked immunosorbent assay was used to measure the plasma levels of sCD40L before and after routine protocol treatments in sixty-four PID patients and seventy healthy controls. Results: The level of plasma sCD40L (pg/ml) was significantly elevated in PID patients (1632.83 ± 270.91) compared to that in normal controls (700.33 ± 58.77; p= 0.001) and decreased significantly as compared to that in the same patients (928.77 ± 177.25; p= 0.0001) after they received treatment. The concentration of sCD40L was significantly correlated with the level of plasma C-reactive protein (CRP) in the blood (r = 0.202, p= 0.01, n = 134). When the cutoff level of plasma sCD40L levels was determined to be 1612.26. pg/ml based on ROC, the sensitivity, specificity, and the area under the curve of plasma sCD40L level for predicting PID were 0.26, 0.97, and 0.58 (95% confidence interval: 0.48-0.68), respectively, while the adjusted odds ratio (AOR) with their 95% CI of plasma sCD40L for PID risk was 7.09 (95% CI = 1.14-43.87, p= 0.03). Conclusions: The expression of plasma sCD40L was increased in patients with PID and detection of plasma sCD40L could be useful for the diagnosis of PID.

Original languageEnglish
Pages (from-to)236-240
Number of pages5
JournalClinica Chimica Acta
Volume438
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Pelvic Inflammatory Disease
CD40 Ligand
Plasmas
C-Reactive Protein
Immunosorbents
Clinical Protocols
Area Under Curve
Blood Proteins
Assays
Blood
Biomarkers
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Confidence Intervals
Sensitivity and Specificity

Keywords

  • Pelvic inflammatory disease (PID)
  • Plasma
  • Soluble CD40 ligand (sCD40L)

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

Increased plasma soluble CD40 ligand concentration in pelvic inflammatory disease. / Ho, Tsung chin; Yang, Shun Fa; Wang, Po Hui; Lin, Long Yau; Tee, Yi Torng; Liao, Wen Chun; Chang, Hsiu-Ju; Tsai, Hsiu-Ting.

In: Clinica Chimica Acta, Vol. 438, 01.01.2015, p. 236-240.

Research output: Contribution to journalArticle

Ho, Tsung chin ; Yang, Shun Fa ; Wang, Po Hui ; Lin, Long Yau ; Tee, Yi Torng ; Liao, Wen Chun ; Chang, Hsiu-Ju ; Tsai, Hsiu-Ting. / Increased plasma soluble CD40 ligand concentration in pelvic inflammatory disease. In: Clinica Chimica Acta. 2015 ; Vol. 438. pp. 236-240.
@article{da2390c9e8f743d2b87ba65e774563d7,
title = "Increased plasma soluble CD40 ligand concentration in pelvic inflammatory disease",
abstract = "Background: The role of soluble CD40 ligand (sCD40L) in pelvic inflammatory disease (PID) remains unclear. We sought to determine whether sCD40L was an efficient serum marker as with WBC and CRP in PID patients. Methods: Enzyme-linked immunosorbent assay was used to measure the plasma levels of sCD40L before and after routine protocol treatments in sixty-four PID patients and seventy healthy controls. Results: The level of plasma sCD40L (pg/ml) was significantly elevated in PID patients (1632.83 ± 270.91) compared to that in normal controls (700.33 ± 58.77; p= 0.001) and decreased significantly as compared to that in the same patients (928.77 ± 177.25; p= 0.0001) after they received treatment. The concentration of sCD40L was significantly correlated with the level of plasma C-reactive protein (CRP) in the blood (r = 0.202, p= 0.01, n = 134). When the cutoff level of plasma sCD40L levels was determined to be 1612.26. pg/ml based on ROC, the sensitivity, specificity, and the area under the curve of plasma sCD40L level for predicting PID were 0.26, 0.97, and 0.58 (95{\%} confidence interval: 0.48-0.68), respectively, while the adjusted odds ratio (AOR) with their 95{\%} CI of plasma sCD40L for PID risk was 7.09 (95{\%} CI = 1.14-43.87, p= 0.03). Conclusions: The expression of plasma sCD40L was increased in patients with PID and detection of plasma sCD40L could be useful for the diagnosis of PID.",
keywords = "Pelvic inflammatory disease (PID), Plasma, Soluble CD40 ligand (sCD40L)",
author = "Ho, {Tsung chin} and Yang, {Shun Fa} and Wang, {Po Hui} and Lin, {Long Yau} and Tee, {Yi Torng} and Liao, {Wen Chun} and Hsiu-Ju Chang and Hsiu-Ting Tsai",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.cca.2014.08.030",
language = "English",
volume = "438",
pages = "236--240",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Increased plasma soluble CD40 ligand concentration in pelvic inflammatory disease

AU - Ho, Tsung chin

AU - Yang, Shun Fa

AU - Wang, Po Hui

AU - Lin, Long Yau

AU - Tee, Yi Torng

AU - Liao, Wen Chun

AU - Chang, Hsiu-Ju

AU - Tsai, Hsiu-Ting

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: The role of soluble CD40 ligand (sCD40L) in pelvic inflammatory disease (PID) remains unclear. We sought to determine whether sCD40L was an efficient serum marker as with WBC and CRP in PID patients. Methods: Enzyme-linked immunosorbent assay was used to measure the plasma levels of sCD40L before and after routine protocol treatments in sixty-four PID patients and seventy healthy controls. Results: The level of plasma sCD40L (pg/ml) was significantly elevated in PID patients (1632.83 ± 270.91) compared to that in normal controls (700.33 ± 58.77; p= 0.001) and decreased significantly as compared to that in the same patients (928.77 ± 177.25; p= 0.0001) after they received treatment. The concentration of sCD40L was significantly correlated with the level of plasma C-reactive protein (CRP) in the blood (r = 0.202, p= 0.01, n = 134). When the cutoff level of plasma sCD40L levels was determined to be 1612.26. pg/ml based on ROC, the sensitivity, specificity, and the area under the curve of plasma sCD40L level for predicting PID were 0.26, 0.97, and 0.58 (95% confidence interval: 0.48-0.68), respectively, while the adjusted odds ratio (AOR) with their 95% CI of plasma sCD40L for PID risk was 7.09 (95% CI = 1.14-43.87, p= 0.03). Conclusions: The expression of plasma sCD40L was increased in patients with PID and detection of plasma sCD40L could be useful for the diagnosis of PID.

AB - Background: The role of soluble CD40 ligand (sCD40L) in pelvic inflammatory disease (PID) remains unclear. We sought to determine whether sCD40L was an efficient serum marker as with WBC and CRP in PID patients. Methods: Enzyme-linked immunosorbent assay was used to measure the plasma levels of sCD40L before and after routine protocol treatments in sixty-four PID patients and seventy healthy controls. Results: The level of plasma sCD40L (pg/ml) was significantly elevated in PID patients (1632.83 ± 270.91) compared to that in normal controls (700.33 ± 58.77; p= 0.001) and decreased significantly as compared to that in the same patients (928.77 ± 177.25; p= 0.0001) after they received treatment. The concentration of sCD40L was significantly correlated with the level of plasma C-reactive protein (CRP) in the blood (r = 0.202, p= 0.01, n = 134). When the cutoff level of plasma sCD40L levels was determined to be 1612.26. pg/ml based on ROC, the sensitivity, specificity, and the area under the curve of plasma sCD40L level for predicting PID were 0.26, 0.97, and 0.58 (95% confidence interval: 0.48-0.68), respectively, while the adjusted odds ratio (AOR) with their 95% CI of plasma sCD40L for PID risk was 7.09 (95% CI = 1.14-43.87, p= 0.03). Conclusions: The expression of plasma sCD40L was increased in patients with PID and detection of plasma sCD40L could be useful for the diagnosis of PID.

KW - Pelvic inflammatory disease (PID)

KW - Plasma

KW - Soluble CD40 ligand (sCD40L)

UR - http://www.scopus.com/inward/record.url?scp=84907168809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907168809&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.08.030

DO - 10.1016/j.cca.2014.08.030

M3 - Article

C2 - 25192781

AN - SCOPUS:84907168809

VL - 438

SP - 236

EP - 240

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -